GO:0032686 negative regulation of hepatocyte growth factor production: Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032686 describes any biological process that reduces the amount of hepatocyte growth factor (HGF) produced by a cell, acting at transcriptional, post-transcriptional or secretory levels.
• The term is a negative regulatory node within the broader HGF production axis, which controls liver regeneration, tissue repair and tumour invasion.
• CCL5 (RANTES) is a validated extracellular suppressor of reparative macrophage-derived HGF, acting through FOXO3a.
• Notch signalling provides a negative feedback loop that restrains Met-dependent invasive growth, indirectly limiting HGF-driven phenotypes.
• Macrophage-intrinsic pathways such as MST1-PPARγ-CD36 and NF-κB modulate the inflammatory microenvironment in which HGF production is tuned.
• CRISPR knockout, knock-in and overexpression models are the standard tools for dissecting causal regulators of GO:0032686 in hepatocytes and macrophages.
Description
GO:0032686, negative regulation of hepatocyte growth factor production, is a Gene Ontology biological process term that captures any mechanism which decreases the amount of hepatocyte growth factor (HGF) synthesised and released by a cell. HGF is a pleiotropic cytokine best known for driving hepatocyte proliferation during liver regeneration, and its production is tightly controlled because excessive or misplaced HGF signalling promotes invasive growth and tumour progression. The term therefore sits at the intersection of regenerative biology, inflammation and oncology. Researchers study GO:0032686 to understand how tissues switch HGF production off after injury has resolved, and how tumours or fibrotic niches escape that brake. Because HGF acts predominantly in a paracrine manner, negative regulation can occur in the producing cell (for example, a reparative macrophage or a stromal fibroblast) even when the responding cell is a hepatocyte or carcinoma cell. This makes the term experimentally tractable: one can measure HGF mRNA, intracellular pro-HGF and secreted HGF in the producer population after genetic or pharmacological perturbation. The ontology term is deliberately broad, encompassing transcriptional repression, mRNA destabilisation, impaired translation and blocked secretion, and it is defined by outcome rather than by a single molecular mechanism.
negative regulation of hepatocyte growth factor production At A Glance
| GO ID | GO:0032686 |
|---|---|
| GO term | negative regulation of hepatocyte growth factor production |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Reduces the amount of HGF produced by a cell, thereby limiting HGF-dependent paracrine signalling |
| Regulated entity | hepatocyte growth factor (HGF) production |
| Direction | Negative regulation (down-regulation) |
| Representative regulators | CCL5, FOXO3a, Notch, MST1, PPARγ, NF-κB |
| Physiological context | Resolution of liver regeneration, muscle regeneration, control of invasive growth |
| Disease relevance | Liver fibrosis, gallbladder carcinoma metastasis, melanoma biology |
What Is GO:0032686?
In plain terms, GO:0032686 refers to any process that stops or slows the production of hepatocyte growth factor. It is a negative regulation term, meaning the regulated entity is the production of HGF rather than HGF activity itself. The regulation can act on transcription of the HGF gene, on stability or translation of HGF mRNA, on processing of the pro-HGF precursor, or on secretion of mature HGF. Because the term is defined by its effect, many different signalling inputs can be annotated to it, including chemokines, growth factors and intracellular kinases that converge on the HGF-producing cell.
Why Is negative regulation of hepatocyte growth factor production Important in Cell Biology?
GO:0032686 matters because HGF is one of the most potent hepatocyte mitogens and a driver of invasive growth, so the ability to switch its production off is as important as the ability to switch it on. When negative regulation fails, persistent HGF supply can sustain chronic proliferation, fibrosis or tumour metastasis; when it is excessive, regeneration after injury may be impaired. Understanding the term therefore informs regenerative medicine, oncology and immunology, and it provides a defined ontology handle for annotating high-throughput datasets in which HGF is differentially produced.
• Controls termination of liver regeneration after injury, preventing unchecked hepatocyte proliferation.
• Limits reparative macrophage-derived HGF, which is a key paracrine source during tissue repair.
• Provides a brake on Met-dependent invasive growth through feedback loops such as Notch.
• Modulates the tumour microenvironment in gallbladder carcinoma and other HGF-responsive cancers.
• Interacts with inflammatory signalling, including NF-κB and PPARγ pathways in macrophages.
• Is relevant to fibrotic liver disease, where macrophage phenotype determines HGF output.
• Offers a mechanistic explanation for why chemokines such as CCL5 confine regeneration.
• Supports annotation of RNA-seq and proteomic datasets in regenerative and cancer studies.
• Connects to endocrine and growth-factor networks that regulate liver growth.
• Provides a testable node for CRISPR screens aimed at identifying HGF-suppressing genes.
What Happens During negative regulation of hepatocyte growth factor production?
Extracellular signals that initiate suppression
In simple terms: A signal from outside the cell tells the HGF-producing cell to make less HGF.
Negative regulation of HGF production typically begins with an extracellular cue. The chemokine CCL5 acts on reparative macrophages and down-regulates their production of HGF, thereby confining liver regeneration. In muscle regeneration, activated macrophages are a prominent source of HGF, and their production profile is dynamically controlled early in the repair process. Growth-factor and cytokine networks, including insulin-like growth factor signalling, contribute to the broader regulation of liver growth in which HGF production is embedded. These inputs ensure that HGF output is matched to the physiological state of the tissue.
Intracellular signalling and transcription-factor control
In simple terms: Inside the cell, signalling cascades switch transcription factors on or off, and these factors control the HGF gene.
Once an extracellular cue is received, intracellular cascades relay it to transcription factors. CCL5-mediated suppression of macrophage HGF depends on forkhead box O 3a (FOXO3a), demonstrating that a specific transcription factor can execute GO:0032686. In macrophages, MST1 signalling promotes the PPARγ-CD36 pathway and suppresses NF-κB signalling, shaping the inflammatory state that governs HGF production. Notch activation provides a negative feedback loop that restrains Met-dependent invasive growth, indirectly opposing HGF-driven phenotypes. Together these pathways illustrate that GO:0032686 is executed through defined transcriptional programmes rather than by a single universal repressor.
Transcriptional and post-transcriptional reduction of HGF output
In simple terms: The cell makes fewer HGF messages and/or fewer HGF proteins.
At the level of the HGF gene, negative regulation can reduce transcription, destabilise HGF mRNA or impair its translation. Experimentally, this is detected as decreased HGF mRNA and decreased intracellular pro-HGF in the producer cell. Because HGF is secreted, a reduction in production is ultimately reflected in lower extracellular HGF available to neighbouring cells. The ontology term encompasses all of these levels, which is why researchers often combine transcript and protein readouts when annotating GO:0032686.
Feedback loops that maintain the suppressed state
In simple terms: Once HGF is turned down, feedback loops help keep it down.
Negative regulation is often self-reinforcing. Notch-mediated negative feedback restrains Met-dependent invasive growth, providing a feedback architecture that limits HGF-driven signalling. In the liver, the balance between pro-regenerative and anti-regenerative signals determines whether HGF production remains suppressed or is re-activated. Activins and related TGF-β superfamily ligands participate in the broader control of liver health and disease, contributing to the signalling environment in which HGF production is tuned. These loops are important because they determine the duration, not just the magnitude, of suppression.
Resolution of regeneration and return to homeostasis
In simple terms: When repair is finished, HGF production is switched off so the tissue can return to normal.
The physiological endpoint of GO:0032686 is the termination of HGF-dependent proliferation once tissue repair is complete. CCL5-mediated suppression of macrophage-derived HGF confines liver regeneration, preventing uncontrolled growth. In muscle, HGF production by activated macrophages is an early event that is subsequently resolved. Failure to resolve HGF production can contribute to fibrosis or persistent proliferative signalling, which is why the term is clinically relevant.
Key Genes Involved in GO:0032686 negative regulation of hepatocyte growth factor production
The following genes and proteins have been experimentally linked to the control of HGF production or to the signalling environment in which GO:0032686 operates.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HGF | Encodes hepatocyte growth factor, the production of which is negatively regulated | Direct readout for GO:0032686 assays |
| CCL5 | Chemokine that down-regulates reparative macrophage-derived HGF | Validated extracellular suppressor of HGF production |
| FOXO3a | Transcription factor required for CCL5-mediated HGF suppression | Mechanistic effector of GO:0032686 |
| NOTCH1 | Receptor mediating negative feedback on Met-dependent invasive growth | Feedback regulator opposing HGF-driven phenotypes |
| MET | Receptor tyrosine kinase for HGF; its signalling is restrained by Notch feedback | Connects GO:0032686 to invasive growth control |
| MST1 | Macrophage kinase promoting PPARγ-CD36 and suppressing NF-κB | Modulates the inflammatory niche controlling HGF production |
| PPARG | Nuclear receptor in the MST1-controlled pathway | Candidate modifier of macrophage HGF output |
| CD36 | Scavenger receptor downstream of PPARγ in macrophages | Part of the pathway that shapes HGF-producing macrophage states |
| NFKB1 | Transcription factor suppressed by MST1 signalling | Inflammatory regulator of the HGF production microenvironment |
| FOXA1 | Transcription factor regulated by TGF-β1 with m6A-dependent translation | Links TGF-β signalling to HGF-related tumour biology |
| TGFB1 | Cytokine that regulates FOXA1 translation efficiency | Upstream signal in HGF-associated carcinoma models |
| IGF1 | Growth factor implicated in regulation of liver growth | Endocrine context for HGF production control |
| MITF | Melanogenesis transcription factor suppressed by HGF-ERK signalling | Illustrates HGF-responsive biology beyond the liver |
| MAPK1 | ERK kinase mediating HGF-dependent nuclear exclusion of MITF | Signalling node downstream of HGF |
| ACTIVIN A | TGF-β superfamily ligand active in liver health and disease | Signalling context for HGF production regulation |
| CD68 | Macrophage marker used to identify HGF-producing cells | Cell-identity marker in HGF production studies |
How Is negative regulation of hepatocyte growth factor production Regulated?
GO:0032686 is itself regulated at multiple levels. Extracellularly, chemokines such as CCL5 suppress macrophage-derived HGF in a FOXO3a-dependent manner, providing a defined inhibitory input. Intracellularly, kinase pathways including MST1 shape the macrophage state through PPARγ-CD36 and NF-κB, indirectly controlling HGF production. Feedback loops such as Notch-mediated restraint of Met signalling limit HGF-driven phenotypes and help maintain the suppressed state. Growth-factor networks, including insulin-like growth factor signalling, contribute to the endocrine and paracrine context in which liver growth and HGF production are coordinated. TGF-β superfamily signalling, including activins, further modulates the liver microenvironment relevant to HGF regulation.
negative regulation of hepatocyte growth factor production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CCL5 / FOXO3a | Liver regeneration confinement and fibrosis | Macrophage-specific KO and FOXO3a reporter knock-in in mouse liver injury models |
| MST1 / PPARG | Schistosomiasis-induced liver fibrosis | Macrophage MST1 knockout with PPARγ pathway readouts |
| NOTCH1 / MET | Met-dependent invasive growth and cancer | Notch gain-of-function and Met-driven invasion assays |
| TGFB1 / FOXA1 | Gallbladder carcinoma metastasis | TGF-β1-treated carcinoma cells with FOXA1 translation reporters |
| HGF / MITF | Melanogenesis and pigmentation | HGF-treated melanocytes with ERK and MITF localisation assays |
Liver fibrosis and chronic liver disease
Macrophage phenotype is a major determinant of HGF production in the injured liver. MST1 signalling in macrophages protects against schistosomiasis-induced liver fibrosis by promoting the PPARγ-CD36 pathway and suppressing NF-κB signalling, a pathway that shapes the HGF-producing niche. Activins and related TGF-β superfamily ligands are active in liver health and disease and contribute to the signalling environment that governs HGF production. Loss of negative regulation of HGF production may therefore contribute to persistent fibrogenic or proliferative signalling after injury.
Cancer and metastasis
HGF-Met signalling is a well-established driver of invasive growth, and negative feedback loops that restrain this axis are relevant to cancer. Notch provides a negative feedback mechanism that limits Met-dependent invasive growth, directly connecting GO:0032686 to tumour invasion control. In gallbladder carcinoma, TGF-β1 regulates FOXA1 translation efficiency through m6A modification to facilitate metastasis, illustrating how growth-factor signalling networks intersect with HGF-related tumour biology. These findings support the view that failure of negative regulation can unleash HGF-driven phenotypes.
Regeneration and repair biology
HGF is a key mediator of liver and muscle regeneration, and its production must be switched off once repair is complete. CCL5 confines liver regeneration by down-regulating reparative macrophage-derived HGF in a FOXO3a-dependent manner, providing a direct disease-relevant example of GO:0032686. In muscle regeneration, activated macrophages are an early source of HGF, and their production is dynamically controlled. Dysregulation of this brake could impair or prolong regenerative responses.
Pigmentation and non-hepatic HGF biology
HGF is not restricted to the liver; it also suppresses melanogenesis via ERK-dependent nuclear exclusion of MITF, showing that HGF-responsive programmes extend to other tissues. This broadens the potential disease relevance of GO:0032686 beyond hepatology and oncology, and suggests that negative regulation of HGF production may influence pigmentation biology.
From negative regulation of hepatocyte growth factor production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is gene X required for suppression of HGF production? | CRISPR knockout of gene X in macrophages or hepatocytes followed by HGF ELISA |
| Does a specific point mutation in a regulator alter HGF suppression? | Point-mutation knock-in of the candidate residue with HGF readouts |
| Does a disease-associated variant affect HGF production? | Knock-in of the variant allele and comparison of HGF mRNA and secreted protein |
| Where and when is the regulator expressed relative to HGF? | Tagged knock-in (e.g. fluorescent or epitope tag) and imaging |
| Does forced expression of a candidate gene reduce HGF output? | Overexpression of the candidate gene in HGF-producing cells |
| Which pathways cooperate to suppress HGF? | Combined KO or overexpression with pathway inhibitors and transcriptomics |
How to Study the negative regulation of hepatocyte growth factor production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| HGF ELISA | Secreted HGF protein concentration | Quantifying suppression of HGF production after perturbation |
| Immunocytochemistry | Cellular localisation and identity of HGF-producing cells | Identifying activated macrophages early in muscle regeneration |
| qRT-PCR | HGF mRNA abundance | Detecting transcriptional component of GO:0032686 |
| RNA sequencing | Global transcriptional programme of HGF-producing cells | Pathway discovery in macrophage and liver models |
| Western blot | Intracellular pro-HGF and signalling proteins | Confirming reduced HGF protein and pathway activation |
| Reporter assays | Translation efficiency of candidate regulators | FOXA1 translation control by TGF-β1 |
| Imaging of tagged proteins | Subcellular localisation of regulators | ERK-dependent MITF nuclear exclusion |
| CRISPR perturbation screens | Causal genes controlling HGF output | Identifying novel suppressors of HGF production |
Measuring HGF production directly
The most direct way to study GO:0032686 is to quantify HGF produced by the cell of interest. Enzyme-linked immunosorbent assays detect secreted HGF in conditioned medium, while immunocytochemistry can localise HGF within activated macrophages early in regeneration. Combining secreted-protein measurements with intracellular pro-HGF staining distinguishes reduced production from altered secretion.
Transcript-level analysis
Because negative regulation can act on HGF mRNA, quantitative PCR and RNA sequencing of HGF-producing cells are standard. In CCL5-treated macrophages, reduced HGF production is accompanied by changes in the FOXO3a-dependent transcriptional programme. RNA sequencing of macrophage populations in fibrosis models further reveals pathway-level changes in PPARγ, CD36 and NF-κB targets.
Signalling and pathway interrogation
To identify the mechanism, researchers perturb candidate pathways. Notch gain-of-function and loss-of-function experiments reveal feedback restraint of Met-dependent invasive growth. MST1 manipulation in macrophages demonstrates coupling to PPARγ-CD36 and NF-κB. TGF-β1 treatment with FOXA1 translation reporters links cytokine signalling to downstream translation control.
Imaging and spatial context
Because HGF production is often paracrine, spatial methods matter. Immunocytochemistry identifies which cell types produce HGF in regenerating tissue. Tagged knock-in reporters allow live tracking of regulator expression relative to HGF output, and imaging of ERK-dependent nuclear exclusion of MITF illustrates how HGF-responsive programmes can be visualised in non-hepatic cells.
How CRISPR Can Be Used to Study GO:0032686 negative regulation of hepatocyte growth factor production
Knockout
CRISPR knockout is used to test whether a candidate gene is required for negative regulation of HGF production. For example, deleting FOXO3a would be expected to blunt CCL5-mediated suppression of macrophage HGF, and knockout of MST1 in macrophages alters the PPARγ-CD36 and NF-κB pathways that shape HGF output. Knockout models provide the cleanest loss-of-function evidence for GO:0032686.
Point Mutation
Point-mutation knock-in allows precise testing of phosphorylation sites, DNA-binding residues or disease-associated variants in regulators of HGF production. This is valuable when a domain-level knockout would be lethal or pleiotropic, and it enables separation of the HGF-suppressive function from other activities of the same protein.
Knock-in
Knock-in of reporters or tags (for example, fluorescent or epitope tags on HGF or on a regulator such as FOXO3a) enables tracking of when and where negative regulation occurs. Tagged knock-in lines are also useful for isolating HGF-producing cells for transcriptomic analysis.
Overexpression
Overexpression of a candidate suppressor tests sufficiency: if forced expression of the gene reduces HGF mRNA and secreted protein, it supports a role in GO:0032686. Overexpression of Notch components, for instance, restrains Met-dependent invasive growth, and overexpression approaches complement knockout studies of CCL5-FOXO3a signalling.
How EDITGENE Supports negative regulation of hepatocyte growth factor production Research
Researchers studying negative regulation of hepatocyte growth factor production-related genes often need to determine whether a candidate gene is causally involved in suppressing HGF output, or whether it merely correlates with changes in HGF-producing cell states. Establishing causality requires controlled genetic perturbation in relevant cell types, such as macrophages, hepatocytes or carcinoma cells, combined with quantitative readouts of HGF mRNA and secreted protein. EDITGENE provides the CRISPR tools and cell models needed to move from correlation to mechanism in this pathway.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of hepatocyte growth factor production research.
Frequently Asked Questions About negative regulation of hepatocyte growth factor production
What is GO:0032686?
GO:0032686 is the Gene Ontology biological process term for negative regulation of hepatocyte growth factor production, meaning any process that reduces the amount of HGF a cell produces.
What does negative regulation of hepatocyte growth factor production mean in simple terms?
It means the cell is being told to make less HGF, either by reducing HGF gene expression, HGF mRNA translation or HGF secretion.
What genes are involved in negative regulation of hepatocyte growth factor production?
Reported regulators include CCL5 and FOXO3a, which suppress macrophage-derived HGF, and Notch, which provides negative feedback on Met-dependent invasive growth; MST1, PPARγ, CD36 and NF-κB shape the macrophage state that controls HGF output.
Why is HGF production suppressed during liver regeneration?
Suppressing HGF production helps confine regeneration once repair is complete; CCL5-mediated down-regulation of reparative macrophage HGF limits liver regeneration.
How is HGF production measured in the lab?
Common methods include HGF ELISA for secreted protein, immunocytochemistry for cellular localisation, qRT-PCR for HGF mRNA and RNA sequencing for pathway-level changes.
Which cell types produce HGF that can be negatively regulated?
Activated macrophages are a well-documented source early in muscle regeneration, and reparative macrophages in the liver are a key source whose HGF output is suppressed by CCL5.
Is GO:0032686 relevant to cancer?
Yes. Notch-mediated negative feedback restrains Met-dependent invasive growth, and TGF-β1-FOXA1 signalling contributes to gallbladder carcinoma metastasis, linking HGF-related pathways to tumour progression.
What experimental models are used to study GO:0032686?
CRISPR knockout, point-mutation knock-in, tagged knock-in and overexpression models in macrophages, hepatocytes or carcinoma cells are commonly used, combined with HGF ELISA and transcriptomics.
Does HGF have functions outside the liver?
Yes. HGF suppresses melanogenesis via ERK-dependent nuclear exclusion of MITF, showing that HGF-responsive biology extends beyond hepatology.
How can CRISPR help identify new regulators of HGF production?
Pooled CRISPR knockout or activation screens with HGF secretion or reporter readouts can identify genes whose loss or gain changes HGF production, providing causal evidence for GO:0032686.
Conclusion
GO:0032686, negative regulation of hepatocyte growth factor production, is a compact ontology term that captures an essential biological brake on one of the most potent regenerative and invasive growth factors. Work on CCL5-FOXO3a signalling in reparative macrophages, Notch-mediated feedback on Met, and macrophage MST1-PPARγ-CD36 pathways has begun to define the molecular logic of this suppression. Because HGF production must be switched off for tissues to return to homeostasis, and because failure of this brake can contribute to fibrosis and cancer, the term is a useful anchor for both mechanistic studies and high-throughput annotation. CRISPR-based knockout, knock-in and overexpression models, combined with quantitative HGF readouts, provide the most direct route to establishing causality for candidate regulators of GO:0032686.
References
- 1. Sawano S et al.. 2014. Supplementary immunocytochemistry of hepatocyte growth factor production in activated macrophages early in muscle regeneration.. Anim Sci J 85(12):994-1000 PMID: 25185534
- 2. Wu Z et al.. 2024. TGF-β1 facilitates gallbladder carcinoma metastasis by regulating FOXA1 translation efficiency through m(6)A modification.. Cell Death Dis 15(6):422 PMID: 38886389
- 3. Stella MC et al.. 2005. Negative feedback regulation of Met-dependent invasive growth by Notch.. Mol Cell Biol 25(10):3982-96 PMID: 15870272
- 4. Skrtic S et al.. 2001. Possible roles of insulin-like growth factor in regulation of physiological and pathophysiological liver growth.. Horm Res 55 Suppl 1:1-6 PMID: 11408753
- 5. Huang M et al.. 2022. C-C motif chemokine ligand 5 confines liver regeneration by down-regulating reparative macrophage-derived hepatocyte growth factor in a forkhead box O 3a-dependent manner.. Hepatology 76(6):1706-1722 PMID: 35288960
- 6. Li J et al.. 2024. Macrophage MST1 protects against schistosomiasis-induced liver fibrosis by promoting the PPARγ-CD36 pathway and suppressing NF-κB signaling.. PLoS Pathog 20(12):e1012790 PMID: 39700261
- 7. Hamang M et al.. 2023. Gastrointestinal pharmacology activins in liver health and disease.. Biochem Pharmacol 214:115668 PMID: 37364623
- 8. Lee JH et al.. 2026. Hepatocyte growth factor suppresses melanogenesis via ERK-dependent nuclear exclusion of MITF.. Cell Biosci 16(1) PMID: 42323670
